Article History
Received: 2 April 2018
Accepted: 25 January 2019
First Online: 6 March 2019
Competing interests
: All authors are employees and stockholders of GlaxoSmithKline, a pharmaceutical company that discovers and develops epigenetic therapies for cancer.